Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1991-2-20
|
pubmed:abstractText |
Interleukin 2 (IL-2)-activated peripheral blood mononuclear cells (PBMC) have been reported to lyse tumor cells while essentially sparing normal cells in vitro. This report concerns IL-2-induced anti-keratinocyte (anti-KC) cytotoxic effectors that lyse normal human keratinocytes (KC) in vitro. Effectors were generated by culturing PBMC for 1-8 d in various concentrations of recombinant IL-2 and then assayed against 51Cr-labeled targets. Effectors stimulated with 10(3) U/ml of IL-2 for 8 d readily lysed adherent or trypsinized autologous or allogeneic KC cultured in serum-free medium. Induction of anti-KC effectors was IL-2 dose-dependent, with as little as 12-25 U/ml of IL-2 inducing increased anti-KC activity after 24 h of treatment. Although anti-KC activity was increased after overnight culture in IL-2, maximal effector potency in terms of lytic units (LU) per 10(6) effector cells required 4 d of IL-2 treatment. Maximal effector yield in terms of LU per input PBMC occurred after 8 d of IL-2 treatment. Antibody plus complement depletion studies showed that the anti-KC effectors predominantly have a CD16 --/CD3 --/CD2+ phenotype. A natural killer (NK)-like specificity of the effectors was suggested by two findings: unlabeled K562 cells totally inhibited lysis of 51Cr-KC in cold target competition assays, and interferon gamma (IFN-g) treatment (2.5 U/ml-500 U/ml of recombinant IFN-g for 48-72 h) down-regulated KC susceptibility to lysis by these effectors. Thus, IL-2 treatment of PBMC induces non-T cell, natural killer-like effectors that can lyse both autologous and allogeneic KC. Furthermore, KC resemble other cell types that become resistant to non-MHC-restricted lysis after treatment with IFN-g. Finally, the contrasting effects of IFN-g treatment on KC lysis by these effectors, as opposed to lysis by specific T cells, suggests that IFN-g could promote a shift from non-MHC-restricted to MHC-restricted KC lysis during epidermal immune responses in vivo.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0022-202X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
96
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
127-33
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1987288-Adult,
pubmed-meshheading:1987288-Antigens, CD,
pubmed-meshheading:1987288-Cell Line,
pubmed-meshheading:1987288-Cells, Cultured,
pubmed-meshheading:1987288-Cytotoxicity, Immunologic,
pubmed-meshheading:1987288-Humans,
pubmed-meshheading:1987288-Interleukin-2,
pubmed-meshheading:1987288-Keratinocytes,
pubmed-meshheading:1987288-Killer Cells, Natural,
pubmed-meshheading:1987288-Lymphocytes,
pubmed-meshheading:1987288-Male,
pubmed-meshheading:1987288-Recombinant Proteins
|
pubmed:year |
1991
|
pubmed:articleTitle |
Lysis of keratinocytes by IL-2-activated peripheral blood lymphocytes.
|
pubmed:affiliation |
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|